1
0
0
News
Abnehmpräparate: Dicke Probleme | PZ – Pharmazeutische Zeitung
www.pharmazeutische-zeitung.de
Von Sven Siebenand, Berlin / Die Anzahl der Übergewichtigen wird auch in Deutschland immer größer, das pharmakologische Instrumentarium dagegen immer klein...
Study links blood pressure drugs to cancer | The Independent | The...
www.independent.co.uk
A range of drugs widely used to treat high blood pressure and heart failure may be linked to cancer, study results suggest.
Makers of blood-thinning drug Pradaxa 'put marketing ahead of...
www.abc.net.au
About 30,000 Australians on a new blood-thinning drug could have been put at increased risk of internal bleeding because the drug's makers withheld safety...
New once-daily Striverdi* (olodaterol) Respimat gains approval in...
www.finanznachrichten.de
Phase III trials have shown that once-daily Striverdi Respimat provided fast, remarkable and sustained improvements in lung function when given in addition to...
Network Profiles
LinkedIn: Klaus Dugi – Executive Vice President and Chief Medical ...ch.linkedin.com › klaus-dugi
Sehen Sie sich das Profil von Klaus Dugi auf LinkedIn an, dem weltweit größten beruflichen Netzwerk. 4 Jobs sind im Profil von Klaus Dugi aufgelistet. Sehen ...
Klaus Dugi | Follow[dot]Healthfollow.health › people › klaus-dugi
follow.health
Selected healthcare news for the person - Klaus Dugi. No attempt is made to disambiguate individuals with identical names.
Newsley.com | Recent Financial and Business News: Klaus Dugi
newsley.com
Recent Financial and Business News articles mentioning Klaus Dugi.
Interests
HL activity found to be antiatherogenic - Medscapewww.medscape.com › viewarticle
www.medscape.com
Authors Dr Klaus Dugi (University of Heidelberg, Germany) et al explain that HL activity positively contributes to reverse cholesterol transport, ...
Klaus DUGI - Patents
www.freshpatents.com
Klaus DUGI patents Recent bibliographic sampling of Klaus DUGI patents listed/published in the public domain by the USPTO (USPTO Patent Application …
Boehringer Ingelheim and CureVac announce collaboration to develop...
www.prnewswire.com
With this we hope to be able to develop new treatments and further expand our broad pipeline in lung cancer," said Professor Klaus Dugi, Chief ...
Dabigatran and the monitoring of plasma levels in patients | The BMJ
www.bmj.com
efficacy–safety profile of dabigatran in one of the largest real-world analyses of its
kind comprising 134,000 patients above 65 years. (10). Klaus Dugi, Chief
Medical Officer, Boehringer Ingelheim GmbH, Ingelheim, Germany
Management & Stakeholders
Klaus Dugi - beruflicher Werdegang, Wohn- und Heimatortwww.moneyhouse.ch › list › person › dugi-klaus
www.moneyhouse.ch
1 result for Klaus Dugi, Switzerland. Address, residence, former residences, place and date of birth, age and credit rating.
Business Profiles
patentbuddy: Klaus DUGI
AJINOMOTO CO., INC.
Klaus Dugi Boehringer Ingelheim (Group) [LSE]...
www.life-sciences-europe.com
Life Sciences Business Intelligence Web Portal for European countries
Klaus Dugi Boehringer Ingelheim (Group) [LSG]...
www.life-sciences-germany.com
Life Sciences Business Intelligence Web Portal for Germany, Austria and Switzerland
Education
classmates: Klaus Dugi, Class of Brazil High School - …
Klaus Dugi graduate of Brazil High School in Brazil, IN is on Classmates.com. Get caught up with Klaus Dugi and other high school alumni from Brazil High School.
Books & Literature
Klaus Dugi | XanEdu Customization Platform
www.academicpub.com
Author: Klaus Dugi. Results. Effect of thiol antioxidant on body fat and insulin reactivity Springer Science+Business Media By: Wulf ...
Medizinische Therapie Google Books
books.google.de
Das Nachschlagewerk für die tägliche Arbeit in Klinik und Praxis! Aus den Rezensionen zur 1. Auflage:
Medizinische Therapie in Klinik und Praxis - Google Books
books.google.de
Die gesamte internistische Therapie mit einem Griff!Erfahrene Autoren aus Deutschland, Österreich und der Schweiz behandeln kompakt und umfassend alle...
Insulin glargine product receives European marketing authorization
www.healio.com
Eli Lilly and Company and Boehringer Ingelheim have been granted marketing authorization by the European Commission for their insulin glargine product,...
Related Documents
Deputy Town Mayor Attends Boehringer Ingelheim's Ground Breaking...
bracknelltowncouncil.gov.uk
Deputy Town Mayor Attends Boehringer Ingelheim's Ground Breaking Ceremony
Scientific Publications
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of...
www.ncbi.nlm.nih.gov
employee of Boehringer Ingelheim. Alexandra Marquart is an employee of
Boehringer Ingelheim. Sabine Pinnetti is an employee of Boehringer Ingelheim.
Hans. J. Woerle is an employee of Boehringer Ingelheim. Klaus Dugi is an ...
Diabetes mellitus | www.scienceinschool.org
www.scienceinschool.org
The incidence of diabetes is on the rise, in both the developed and developing worlds. Klaus Dugi, Professor of Medicine at the University of Heidelberg,...
FDA committee unanimously recommends approval of NCBIwww.ncbi.nlm.nih.gov › pmc › articles › PMC
www.ncbi.nlm.nih.gov
... an important step in advancing care for patients with atrial fibrillation', said Prof Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim.
Publications
Publications Authored by Klaus Dugi | PubFactswww.pubfacts.com › author › Klaus+Dugi
www.pubfacts.com
Diabetologia Sep 7;57(9): Epub Jun 7. Drug Metabolism and Pharmacokinetics, Development, Boehringer Ingelheim Pharma GmbH & Co.
The Epidemiological Boehringer Ingelheim Employee Study ...www.hindawi.com › journals › jobe › abs
www.hindawi.com
Kerstin Kempf,1 Stephan Martin,1 Carmen Döhring,2Klaus Dugi,3 Carolin Wolfram von Wolmar,4 Burkhard Haastert,5 and Michael ...
Störungen des Lipidstoffwechsels | SpringerLink
link.springer.com
Störungen des Lipidstoffwechsels sind häufig. Auf Grund der guten Therapierbarkeit sollte das Lipidprofil insbesondere bei solchen Patienten untersucht werden,...
Störungen des Lipidstoffwechsels | SpringerLinklink.springer.com › chapter
link.springer.com
Störungen des Lipidstoffwechsels. Authors; Authors and affiliations. Klaus Dugi. Klaus Dugi. There are no affiliations available. Chapter. 38 Downloads.
Video & Audio
ESHRE Interview - Prof Klaus Dugi - YouTubewww.youtube.com › watch
www.youtube.com
▶ 21:04An interview with Prof Klaus Dugi (Chief Medical Officer and Executive Vice President, Ferring) at this year's ...
PharmaTelevision - Driving success by listening to the customers.
www.pharmatelevision.com
Professor Klaus Dugi, Senior Vice President Medicine at Boehringer Ingelheim talks to Fintan Walton about how they wil drive success by listening to their customers.
Reports & Statements
corporate vice president - French translation – Lingueewww.linguee.com › english-french › corporate+vice+pr...
www.linguee.com
Klaus Dugi, Corporate Vice President Medical Affairs at [...] Boehringer Ingelheim. boehringer-ingelheim.ca. boehringer-ingelheim.ca. Ces progrès sont ...
ESHRE Interview - Prof Klaus Dugi - European Medical ...www.emg-health.com › omnipresent › eshre intervi...
www.emg-health.com
An interview with Prof Klaus Dugi (Chief Medical Officer and Executive Vice President, Ferring) at this year's ...
Klaus Dugi | Latest news on Klaus Dugi | Klaus Dugi photos - Rediff...
realtime.rediff.com
Get the latest news on Klaus Dugi. View Klaus Dugi photos and latest Klaus Dugi news and updates by Rediff Realtime News search.
Klaus Dugi Archivi - AboutPharma
www.aboutpharma.com
“Farmaci inaccessibili? Crimini contro l’umanità” (Redazione Aboutpharma Online) Con i tagli ai finanziamenti la Sanità non migliora (Francesco Corcione - presidente Società …
Miscellaneous
Klaus. Dugi | LinkedIn
www.linkedin.com
View Klaus. Dugi's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Klaus. Dugi discover inside connections …
CA A1 - Crystalline form of 1´-(1-methylethyl)- 4´-[(2 ...www.google.com › patents
patents.google.com
... Boehringer Ingelheim International Gmbh, Gerd Kraemer, Hans-Juergen Martin, Gebhard Adelgoss, Klaus Dugi, Adil Duran, Peter Eickelmann, Steffen Maier, ...
Ferring Appoints Klaus Dugi as Executive Vice Yahoo Finance
finance.yahoo.com
announced today that Professor Klaus Dugi has been appointed Executive Vice
President and Chief Medical Officer, effective immediately. He will be responsible
for Global Medical Affairs, Quality Assurance and Pharmacovigilance.
Klaus Dugi - Patent applicationswww.patentsencyclopedia.com › inventor › klaus-dugi-2
www.patentsencyclopedia.com
Klaus Dugi. Klaus Dugi, Dresden DE. Patent application number, Description, Published , Treatment of Diabetes - The invention relates to the use ...
Klaus Dugi, Dresden DE - Patent applications
www.patentsencyclopedia.com
Patent application number, Description, Published , Treatment of Diabetes - The invention relates to the use of a monoamine neurotransmitter ...
EULAR Klaus Dugi - The Pharma Letterwww.thepharmaletter.com › listing › klaus-dugi
www.thepharmaletter.com
EULAR Klaus Dugi ... Ingelheim has announced data from the pivotal Phase III VOLTAIRE-RA study confirm that its… Filter. Current filters: Klaus Dugi.
Ferring nombra a Klaus Dugi como Vicepresidente Ejecutivo y Director...
www.economiadehoy.es
Será responsable de Global Medical Affairs, Garantía de Calidad y Farmacovigilancia. Además, también será miembro de la Junta Ejecutiva de Ferring.
Accettata domanda di AIC per nintedanib nella Fibrosi Polmonare...
www.notiziariochimicofarmaceutico.it
con esito infausto; pertanto c'è un una forte esigenza insoddisfatta di terapie
efficaci che possano rallentarne la progressione – ha dichiarato Klaus Dugi,
Chief Medical Officer, Boehringer Ingelheim – L'accettazione della ...
Boehringer Ingelheim Corporation Release: OFEV® (Nintedanib*)...
www.biospace.com
• Nintedanib* slows disease progression by reducing the decline in lung function by 50% in a broad range of IPF patient types** •
Boehringer Ingelheim CureVac Partner On Lung Cancer Immunotherapy
www.bioprocessonline.com
Boehringer Ingelheim has obtained exclusive rights to develop and market CureVac’s investigational lung cancer immunotherapy. Announced in a...
COPD Drug, Striverdi Respimat, Receives FDA Approval
www.medicaldaily.com
The Food and Drug Administration on Thursday approved the drug Striverdi Respimat for treatment of chronic obstructive pulmonary disease.
Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m
www.biopharma-reporter.com
With this we hope to be able to develop new treatments and further expand our broad pipeline in lung cancer,” said Professor Klaus Dugi, Chief ...
FDA Grants AML Drug Volasertib Orphan Drug Designation
www.cancernetwork.com
alternative for those patients who are currently left with limited options,” said Klaus Dugi, MD, the chief medical officer at Boehringer Ingelheim, in a press
release. The drug is a selective inhibitor of Polo-like kinase 1 (Plk1); ...
FT Digital Health Summit Europe
event.ft-live.com
Chief Medical Officer England. Murray Stewart Chief Medical Officer
GlaxoSmithKline, Klaus Dugi Senior Vice President Medicine and Chief Medical
Officer Boehringer Ingelheim ...
La Coalición Mundial del Cáncer de Pulmón y Boehringer Ingelheim...
www.boehringer-ingelheim.es
mejor –afirma el profesor Klaus Dugi, vicepresidente sénior corporativo del
Departamento Médico de Boehringer Ingelheim–. La información extraída de la
encuesta nos ayudará a desarrollar estrategias más eficaces para mejorar las
vidas de ...
Asthma: Boehringer Ingelheim announces U.S. FDA filing ...www.boehringer-ingelheim.pt › press-release › asthma-...
www.boehringer-ingelheim.pt
Professor Klaus Dugi, Chief Medical Officer Professor Klaus Dugi, Chief Medical Officer. "We know that patients who experience asthma symptoms have about a ...
EMA advisory panel backs Lilly/BI's empagliflozin - MM&M - Medical...
www.mmm-online.com
The Committee for Medicinal Products for Human Use endorses the SGLT-2 inhibitor. The FDA refused to approve the drug earlier this month because of...
Cookie Policy – Seraquinwww.seraquin.co.uk › cookie-policy
www.seraquin.co.uk
. Directors: Klaus Dugi (Managing) Mr B Moynihan (Finance & Administration) Registered in England ...
EC Approves Lilly And BI’s Insulin Glargine Product
www.outsourcedpharma.com
... and patients with another option to meet their insulin treatment needs,” said Professor Klaus Dugi, CMO of Boehringer Ingelheim.
FDA Grants Orphan Drug Designation To Boehringer Ingelheim’s...
www.outsourcedpharma.com
Klaus Dugi, CMO at Boehringer Ingelheim said, “Due to the targeted way in which volasertib works, we hope it will offer a new alternative for ...
Related search requests for Klaus Dugi
| Masahiro Takeuchi |
People Forename "Klaus" (14706) Name "Dugi" (39) |
sorted by relevance / date